Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Cancer Discov. 2020 Nov 24;11(2):308–325. doi: 10.1158/2159-8290.CD-20-1408

Figure 4:

Figure 4:

(A) Comparison of the baseline primary versus metastatic tumor molecular profiles in each of 80 enrolled patients, demonstrating concordant (black) or discordant (red) biomarker assignments. IO: Immuno-oncology, group-1; CPS, combined positivity score; HER2 amplified, group-2; EGFR amplified, group-3; FGFR2 amplified, group-4; MET amplified, group-5; MAPK/PIK3CA or ‘KRAS-like’; group-6; all-negative but EGFR expressing by mass-spectrometry, group-7; all-negative or quantity insufficient, group-8. See Table 3 for details on biomarker assignment and treatment algorithm prioritization rules. Figure 4B: Swimmers plot including up to three lines of therapy by modified ITT (mITT) group (top) versus non-mITT group (bottom). Temporal molecular heterogeneity is captured for each patient by colored bars by treatment line for up to 3 lines of therapy.